Tuesday, November 10, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· November 6, 2026

Chesapeake Utilities outlines $550M-$600M 2026 capex plan while advancing $1.2B Florida Energy Pathway toward 2030 in-service

View original at seekingalpha.com

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • No additional ERP O&M until 2028; Q2 2027 go-live on track.

    60% confidence
  • Under the agreement PPC retains 51% ownership with NEER acquiring 49%.

    60% confidence
  • NEER announced as strategic joint venture partner.

    60% confidence
  • Plans to issue $250M long-term debt in Q4, refinancing $100M maturing in December.

    60% confidence
  • WRU expected online in Q1 2027 subject to FERC commissioning.

    60% confidence
  • Adjusted EPS $0.89, up 9%.

    60% confidence
  • WRU full year margin contribution now expected to be $19.7M.

    60% confidence
  • Q3 adjusted gross margin ~$149M up 9%; adjusted net income ~$22M up 11%.

    60% confidence
  • Company invested $151M in Q3 and $413M YTD, on track for full-year guidance of $550M-$600M.

    60% confidence
  • Higher healthcare claims/payroll likely an anomaly in the quarter.

    60% confidence
  • FEP could be expanded without substantial additional capital or much additional pipe.

    60% confidence
  • Transmission expansion projects added $0.09 EPS; FCG interim rates and minor prior rate case increases added $0.09 per share.

    60% confidence
  • WRU total capital now ~$125M, up $25M.

    60% confidence
  • Cape Canaveral LNG facility timeline roughly two to three years; volumes withheld.

    60% confidence
  • Florida PSC staff recommendations expected November 18.

    60% confidence
  • Revolver amended to $650M capacity, up $200M.

    60% confidence
  • FCG rate case in final stages; final commission order expected early January 2027.

    60% confidence
  • FCG settlement not likely; moving toward final commission decision.

    60% confidence
  • No substantive propane margin erosion; natural hedge from storage volumes.

    60% confidence
  • Q3 generated incremental $4.8M from T&D systems and $2.8M margin from infrastructure programs; $2.7M of FCG interim rates recognized.

    60% confidence
  • Gains partly offset by $0.12 higher payroll/benefit costs and $0.09 higher O&M.

    60% confidence
  • FEP permitting expected to take 12-18 months, construction right after, in service 2030.

    60% confidence
  • Regulated segment adjusted gross margin ~$126M; operating income up 13% to ~$56M.

    60% confidence
  • Company is tracking steel prices before committing to first substantive steel obligation for FEP.

    60% confidence
  • SpaceX never considered a principal customer opportunity; existing pipeline being upgraded.

    60% confidence
  • WRU construction essentially complete; pre-commissioning underway.

    60% confidence
  • 2027 margin expectation remains ~$17.2M.

    60% confidence
  • 2028 EPS guidance of $7.75-$8.00 reaffirmed.

    60% confidence
  • Growth trajectory continued through Q3, with 12% increase in adjusted net income and 8% increase in adjusted EPS for the first nine months.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cycle: Data Readouts, FDA Decisions and Capital-Allocation Shifts
From late October to January, mid-cap biotechs move through a dense run of events: ESMO and AHA/AASLD data presentations, Q3 earnings, and FDA PDUFA dates for ivonescimab (Nov 14) and lorundrostat (Dec 22). Alongside the regulatory news, companies are changing how they allocate capital: one lowered FY2026 R&D and SG&A guidance and pushed milestones into 2027, one authorized a $400M buyback, and one scheduled a delisting vote (EGM Nov 19, application Jan 25). Value is concentrating in a few binary regulatory and Phase 3 outcomes (Maritime-1 and ECLIPSE 2/3 readouts around Q1 2027), so sentiment is mixed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,558 source documents archived
Query this data → isubstrate.com